Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER (PFE)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Pfizer : Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 31781) - Meeting

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/17/2017 | 07:16pm CEST

TIME: 8 a.m.

EVENT: Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 31781) holds a meeting of the Arthritis Advisory Committee to discuss supplemental new drug applications 203214 supplement 17, for XELJANZ (tofacitinib) tablets and 208246 supplement 3, for XELJANZ XR (tofacitinib) extended release tablets submitted by Pfizer Inc., for the treatment of adult patients with active psoriatic arthritis.

DATE: August 3, 2017

LOCATION: FDA White Oak Campus, 10903 New Hampshire Avenue, Building 31 Conference Center, the Great Room, Room 1503, Silver Spring, Md.

CONTACT: Philip Bautista, 301-796-9001, AAC@fda.hhs.gov

(c) 2006 Federal Information & News Dispatch, Inc., source Washington Daybook

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
07/26 PFIZER : Second US infliximab biosimilar launched at 35% discount to J&Js Remica..
07/26 PFIZER : Merck and Pfizer Collaborate with Corning
07/25 PFIZER : The Hill - Discussion
07/25 VIIV HEALTHCARE : Announces Superior Efficacy of Dolutegravir Versus Lopinavir/R..
07/25 PFIZER : Backed by partners at Pfizer, eFFECTOR brings its VC total to $150M as ..
07/25 PFIZER : Corning, with assists from Pfizer and Merck, plans $500M pharma glass p..
07/25 PFIZER : Phase II Study Results Showed Comparable Viral Suppression Rates at 96 ..
07/25 PFIZER : Announces Positive Top-Line Results From Comparative Reflections B73910..
07/25DJSamsung Enters U.S. Drug Market -- WSJ
07/24 PFIZER : Health and Human Services Department (HHS); Food and Drug Administratio..
More news
News from SeekingAlpha
07/26 Pfizer's Worrying Trend
07/26 Pfizer Doesn't Want To Be Left In the Dust Of Avastin Biosimilar
07/26 20 Top Stocks For A Monthly Dividend Portfolio
07/26 2nd Quarter Review
07/25 3 THINGS IN BIOTECH YOU SHOULD LEARN : July 25, 2017
Financials ($)
Sales 2017 52 763 M
EBIT 2017 19 898 M
Net income 2017 10 910 M
Debt 2017 23 332 M
Yield 2017 3,87%
P/E ratio 2017 16,80
P/E ratio 2018 14,99
EV / Sales 2017 4,18x
EV / Sales 2018 3,89x
Capitalization 197 115 M
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 37,4 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Mikael Dolsten President-Worldwide Research & Development
Ole Isacson Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER1.91%197 115
JOHNSON & JOHNSON14.47%355 263
NOVARTIS7.35%220 651
ROCHE HOLDING LTD.4.30%220 599
MERCK AND COMPANY5.93%170 565
SANOFI7.50%121 268